Articles

TAL1 activation in T-Cell acute lymphoblastic leukemia: A novel oncogenic 3’ neoenhancer

Université de Paris Cité, Institut Necker Enfants-Malades (INEM), Institut National de la Santé et de la Recherche Médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, 75743 Paris
Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), 69120 Heidelberg
Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), 69120 Heidelberg
Université de Paris Cité, Institut Imagine, Inserm U1163, Paris
Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), 69120 Heidelberg
Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Division of Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg
Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), 69120 Heidelberg
Université de Paris Cité, Institut Necker Enfants-Malades (INEM), Institut National de la Santé et de la Recherche Médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, 75743 Paris
Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), 69120 Heidelberg
Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), 69120 Heidelberg
Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), 69120 Heidelberg
Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), 69120 Heidelberg
Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), 69120 Heidelberg
Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), 69120 Heidelberg
Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), 69120 Heidelberg
Université de Paris Cité, Institut Imagine, Inserm U1163, Paris, France; Department of Hematology, Hôpital Necker Enfants Malades, AP-HP, Faculté de Médecine Paris Descartes, Paris
Aix-Marseille University, Inserm, Theories and Approaches of Genomic Complexity (TAGC), Equipe labellisée Ligue, UMR1090, 13288 Marseille
Université de Paris Cité, Institut Necker Enfants-Malades (INEM), Institut National de la Santé et de la Recherche Médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, 75743 Paris
Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; German Cancer Research Consortium (DKTK), 69120 Heidelberg
Université de Paris Cité, Institut Necker Enfants-Malades (INEM), Institut National de la Santé et de la Recherche Médicale (Inserm) U1151, and Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, 75743 Paris, France; Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), 69120 Heidelberg
Haematologica Early view Jan 12, 2023 https://doi.org/10.3324/haematol.2022.281583